Phagenesis Ltd

Phagenesis Ltd is a pioneering biotechnology company based in the UK, dedicated to advancing therapeutic solutions for patients suffering from neurological disorders. Established with a vision to transform the landscape of neurorehabilitation, Phagenesis focuses on developing innovative treatments that harness the power of phage therapy.

Our core mission is to improve patient outcomes through cutting-edge research and development. We aim to provide effective therapies that not only address symptoms but also target the underlying causes of neurological conditions.

At Phagenesis, we believe in the importance of collaboration and partnership. We work closely with leading academic institutions and healthcare providers to ensure our products are grounded in scientific excellence and clinical relevance.

Our flagship product, currently in clinical trials, showcases our commitment to innovation and efficacy. By leveraging advanced biotechnological methods, we strive to create therapies that are safe, effective, and accessible to all patients in need.

Key Areas of Focus:

• Research and Development: Investing in state-of-the-art research to develop novel therapeutic approaches.
• Clinical Trials: Conducting rigorous clinical trials to validate the safety and efficacy of our products.
• Patient-Centric Solutions: Designing therapies that prioritize patient needs and improve quality of life.

As we look to the future, Phagenesis Ltd is committed to expanding our portfolio of therapies and reaching more patients globally. Our vision is to be at the forefront of neurotherapeutics, making a meaningful difference in the lives of those affected by neurological disorders.